Study S001940

A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05564039
Acronym: SURPASS-SWITCH
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 282
Start: 2022-11-30
Primary completion: 2024-07-15
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes
Interventions: DRUG:Tirzepatide; DRUG:Dulaglutide
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPIH; OTHER:2022-500101-41-00

Registered primary outcomes

Change From Baseline in HbA1c [Baseline, Week 40]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008264	Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. Violante-Ortiz R, BMJ open diabetes research & care	2026	Randomized trial	PMID 41912265 DOI	cites ClinicalTrials.gov:NCT05564039; registry reference DERIVED:41912265
R0005129	Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Billings LK, Annals of internal medicine	2025	Randomized trial	PMID 40183678 DOI	cites ClinicalTrials.gov:NCT05564039; registry reference DERIVED:40183678